<p>For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer. “We can now tell our patients that pembrolizumab after surgery not only delays recurrences but also helps them live longer,” said the study’s lead investigator <a href="https://www.dana-farber.org/find-a-doctor/toni-choueiri">Toni Choueiri, MD</a>, of <a href="https://www.dana-farber.org/">Dana-Farber Cancer Institute</a>.</p>